William Blair Reaffirms “Market Perform” Rating for VistaGen Therapeutics (NASDAQ:VTGN)

VistaGen Therapeutics (NASDAQ:VTGN)‘s stock had its “market perform” rating restated by equities researchers at William Blair in a research report issued to clients and investors on Wednesday, Marketbeat reports.

Other research analysts also recently issued research reports about the company. Stifel Nicolaus downgraded VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price objective on the stock. in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday, October 8th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $0.95.

VistaGen Therapeutics Price Performance

Shares of VistaGen Therapeutics stock opened at $0.74 on Wednesday. The company’s fifty day simple moving average is $4.06 and its 200-day simple moving average is $3.29. The stock has a market capitalization of $29.22 million, a PE ratio of -0.39 and a beta of 0.56. VistaGen Therapeutics has a 1-year low of $0.73 and a 1-year high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The firm had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.16 million. As a group, research analysts anticipate that VistaGen Therapeutics will post -1.77 EPS for the current year.

Institutional Trading of VistaGen Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC lifted its holdings in VistaGen Therapeutics by 246.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company’s stock worth $1,052,000 after purchasing an additional 299,304 shares in the last quarter. AdvisorShares Investments LLC raised its position in shares of VistaGen Therapeutics by 27.7% during the second quarter. AdvisorShares Investments LLC now owns 203,114 shares of the company’s stock valued at $406,000 after buying an additional 44,000 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of VistaGen Therapeutics by 926.0% in the third quarter. Bank of America Corp DE now owns 34,657 shares of the company’s stock worth $123,000 after buying an additional 31,279 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in shares of VistaGen Therapeutics in the third quarter worth $39,000. Finally, Occudo Quantitative Strategies LP bought a new position in shares of VistaGen Therapeutics during the third quarter worth $152,000. Institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.